RESUMEN
The blood-brain barrier is a unique function of the microvasculature in the brain parenchyma that maintains homeostasis in the central nervous system. Blood-brain barrier breakdown is a common pathology in various neurological diseases, such as Alzheimer's disease, stroke, multiple sclerosis, and Parkinson's disease. Traditionally, it has been considered a consequence of neuroinflammation or neurodegeneration, but recent advanced imaging techniques and detailed studies in animal models show that blood-brain barrier breakdown occurs early in the disease process and may precede neuronal loss. Thus, the blood-brain barrier is attractive as a potential therapeutic target for neurological diseases that lack effective therapeutics. To elucidate the molecular mechanism underlying blood-brain barrier breakdown and translate them into therapeutic strategies for neurological diseases, there is a growing demand for experimental models of human origin that allow for functional assessments. Recently, several human induced pluripotent stem cell-derived blood-brain barrier models have been established and various in vitro blood-brain barrier models using microdevices have been proposed. Especially in the Alzheimer's disease field, the human evidence for blood-brain barrier dysfunction has been demonstrated and human induced pluripotent stem cell-derived blood-brain barrier models have suggested the putative molecular mechanisms of pathological blood-brain barrier. In this review, we summarize recent evidence of blood-brain barrier dysfunction in Alzheimer's disease from pathological analyses, imaging studies, animal models, and stem cell sources. Additionally, we discuss the potential future directions for blood-brain barrier research.
RESUMEN
The detailed mechanisms of autoantibody synthesis are different in each disease; however, the dysfunction of immune tolerance is attracting interest as the common mechanism in many autoantibody-associated diseases. Autoantibodies must pass through various physiological barriers, such as the blood-brain barrier, to approach their antigen in the central nervous system. The direct effects of autoantibodies on their antigens vary among antibodies. Exploring the detailed mechanism of synthesis and effect of autoantibodies would provide a more radical and effective therapeutic strategy.
Asunto(s)
Autoanticuerpos , Sistema Nervioso Central , Humanos , Barrera HematoencefálicaRESUMEN
Blood-brain barrier (BBB) dysfunction is a pathological hallmark of many neurodegenerative and neuroinflammatory diseases affecting the central nervous system (CNS). Due to the limited access to disease-related BBB samples, it is still not well understood whether BBB malfunction is causative for disease development or rather a consequence of the neuroinflammatory or neurodegenerative process. Human induced pluripotent stem cells (hiPSCs) therefore provide a novel opportunity to establish in vitro BBB models from healthy donors and patients, and thus to study disease-specific BBB characteristics from individual patients. Several differentiation protocols have been established for deriving brain microvascular endothelial cell (BMEC)-like cells from hiPSCs. Consideration of the specific research question is mandatory for the correct choice of the respective BMEC-differentiation protocol. Here, we describe the extended endothelial cell culture method (EECM), which is optimized to differentiate hiPSCs into BMEC-like cells with a mature immune phenotype, allowing the study of immune cell-BBB interactions. In this protocol, hiPSCs are first differentiated into endothelial progenitor cells (EPCs) by activating Wnt/ß-catenin signaling. The resulting culture, which contains smooth muscle-like cells (SMLCs), is then sequentially passaged to increase the purity of endothelial cells (ECs) and to induce BBB-specific properties. Co-culture of EECM-BMECs with these SMLCs or conditioned medium from SMLCs allows for the reproducible, constitutive, and cytokine-regulated expression of EC adhesion molecules. Importantly, EECM-BMEC-like cells establish barrier properties comparable to primary human BMECs, and due to their expression of all EC adhesion molecules, EECM-BMEC-like cells are different from other hiPSC-derived in vitro BBB models. EECM-BMEC-like cells are thus the model of choice for investigating the potential impact of disease processes at the level of the BBB, with an impact on immune cell interaction in a personalized fashion.
Asunto(s)
Células Endoteliales , Células Madre Pluripotentes Inducidas , Humanos , Células Cultivadas , Encéfalo/fisiología , Barrera Hematoencefálica , Diferenciación Celular/fisiología , FenotipoRESUMEN
Blood-brain barrier (BBB) breakdown and immune cell infiltration into the CNS are early hallmarks of multiple sclerosis (MS). The mechanisms leading to BBB dysfunction are incompletely understood and generally thought to be a consequence of neuroinflammation. Here, we have challenged this view and asked if intrinsic alterations in the BBB of MS patients contribute to MS pathogenesis. To this end, we made use of human induced pluripotent stem cells derived from healthy controls and MS patients and differentiated them into brain microvascular endothelial cell (BMEC)-like cells as in vitro model of the BBB. MS-derived BMEC-like cells showed impaired junctional integrity, barrier properties and efflux pump activity when compared to healthy controls. Also, MS-derived BMEC-like cells displayed an inflammatory phenotype with increased adhesion molecule expression and immune cell interactions. Activation of Wnt/ß-catenin signalling in MS-derived endothelial progenitor cells enhanced barrier characteristics and reduced the inflammatory phenotype. Our study provides evidence for an intrinsic impairment of BBB function in MS patients that can be modelled in vitro. Human iPSC-derived BMEC-like cells are thus suitable to explore the molecular underpinnings of BBB dysfunction in MS and will assist in the identification of potential novel therapeutic targets for BBB stabilization.
Asunto(s)
Células Madre Pluripotentes Inducidas , Esclerosis Múltiple , Humanos , Barrera Hematoencefálica/patología , Esclerosis Múltiple/patología , Células Cultivadas , Células Madre Pluripotentes Inducidas/metabolismo , Encéfalo/fisiologíaRESUMEN
Brain-derived neurotrophic factor (BDNF) cannot cross the blood-brain barrier (BBB) when administered peripherally, which hinders its therapeutic potential. We utilized an in vitro BBB model-a tri-culture of a human endothelial cell line, a pericyte cell line, and an astrocyte cell line-to study the effect of twenty candidate lipophilic compounds on stimulating BDNF secretion in pericytes and astrocytes. The prostaglandin E2 receptor 4 agonist and sphingosine-1-phosphate receptor 5 agonist facilitated secretion of BDNF in the astrocyte, but did not decrease the transendothelial electrical resistance. These compounds may be promising agents for neurodegenerative and neuroinflammatory diseases.
Asunto(s)
Astrocitos/metabolismo , Barrera Hematoencefálica , Factor Neurotrófico Derivado del Encéfalo/biosíntesis , Técnicas de Cocultivo/métodos , Células Cultivadas , Humanos , Subtipo EP4 de Receptores de Prostaglandina E/agonistas , Receptores de Esfingosina-1-Fosfato/agonistasRESUMEN
BACKGROUND AND OBJECTIVES: To evaluate the pathophysiology of neuromyelitis optica spectrum disorder (NMOSD) and the therapeutic mechanism and levels of interleukin-6 (IL-6) blockade (satralizumab), especially with respect to blood-brain barrier (BBB) disruption with the new in vitro and ex vivo human BBB models and in vivo model. METHODS: We constructed new static in vitro and flow-based ex vivo models for evaluating continued barrier function, leukocyte transmigration, and intracerebral transferability of neuromyelitis optica-immunoglobulin G (NMO-IgG) and satralizumab across the BBB using the newly established triple coculture system that are specialized to closely mimic endothelial cell contact of pericytes and endfeet of astrocytes. In the in vivo study, we assessed the effects of an anti-IL-6 receptor antibody for mice (MR16-1) on in vivo BBB disruption in mice with experimental autoimmune encephalomyelitis in which IL-6 concentration in the spinal cord dramatically increases. RESULTS: In vitro and ex vivo experiments demonstrated that NMO-IgG increased intracerebral transferability of satralizumab and NMO-IgG and that satralizumab suppressed the NMO-IgG-induced transmigration of T cells and barrier dysfunction. In the in vivo study, the blockade of IL-6 signaling suppressed the migration of T cells into the spinal cord and prevented the increased BBB permeability. DISCUSSION: These results suggest that (1) our triple-cultured in vitro and in ex vivo BBB models are ideal for evaluating barrier function, leukocyte transmigration, and intracerebral transferability; (2) NMO-IgG increased the intracerebral transferability of NMO-IgG via decreasing barrier function and induced secretion of IL-6 from astrocytes causing more dysfunction of the barrier and disrupting controlled cellular infiltration; and (3) satralizumab, which can pass through the BBB in the presence of NMO-IgG, suppresses the BBB dysfunction and the infiltration of inflammatory cells, leading to prevention of onset of NMOSD.
Asunto(s)
Anticuerpos Bloqueadores/farmacología , Autoanticuerpos/farmacología , Barrera Hematoencefálica , Encefalomielitis Autoinmune Experimental/inmunología , Interleucina-6/inmunología , Neuromielitis Óptica , Animales , Anticuerpos Monoclonales Humanizados/farmacología , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/fisiopatología , Células Cultivadas , Técnicas de Cocultivo , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunoglobulina G , Ratones , Ratones Endogámicos C57BL , Neuromielitis Óptica/inmunología , Neuromielitis Óptica/prevención & controlRESUMEN
The Diagnostic process of neurological disorders consists of anatomical and etiological diagnoses, and that of neuropathies usually starts with a suspicion of peripheral nerve disturbance based on neurological findings, which is subsequently confirmed by electrophysiology. However, there are numerous pitfalls in interpreting neurological features and electrophysiological data in the anatomical diagnosis process, possibly leading to misdiagnoses of "neuropathy" in patients with myelopathies, myopathies, neuromuscular junction diseases, or motor neuron diseases. We present the case of a 7-year-old girl showing acute flaccid quadriplegia with overt abnormalities in a nerve conduction study who was initially misdiagnosed with Guillain-Barré syndrome. In retrospect, we recognize several points suggestive of disorders other than neuropathy.
Asunto(s)
Enfermedades del Sistema Nervioso Periférico/diagnóstico , Niño , Errores Diagnósticos , Femenino , Síndrome de Guillain-Barré , Humanos , Examen NeurológicoRESUMEN
Isolated adrenocorticotropic hormone deficiency (IAD) is a cause of adrenal insufficiency (AI), which shows impaired secretion of adrenocorticotropic hormone (ACTH) with the preserved secretion of other anterior pituitary gland hormones. We herein report a case of IAD complicated by chronic thyroiditis presenting with neuropsychiatric symptoms without other signs indicative of AI that showed complete improvement of the cognitive function after the administration of corticosteroids. The clinical features of our case may be confused with autoimmune encephalopathies (AEs); however, IAD should be strictly differentiated from AEs, as it requires permanent hormone replacement without addition of immunosuppressive agents.
Asunto(s)
Hormona Adrenocorticotrópica/deficiencia , Disfunción Cognitiva/diagnóstico , Encefalitis/diagnóstico , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades Genéticas Congénitas/diagnóstico , Enfermedad de Hashimoto/diagnóstico , Hipoglucemia/diagnóstico , Hormona Adrenocorticotrópica/metabolismo , Enfermedades Autoinmunes/diagnóstico , Encefalopatías/diagnóstico , Disfunción Cognitiva/etiología , Disfunción Cognitiva/psicología , Diagnóstico Diferencial , Electroencefalografía , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/tratamiento farmacológico , Enfermedades del Sistema Endocrino/psicología , Enfermedades Genéticas Congénitas/complicaciones , Enfermedades Genéticas Congénitas/tratamiento farmacológico , Enfermedades Genéticas Congénitas/psicología , Enfermedad de Hashimoto/complicaciones , Terapia de Reemplazo de Hormonas , Humanos , Hidrocortisona/uso terapéutico , Hipoglucemia/complicaciones , Hipoglucemia/tratamiento farmacológico , Hipoglucemia/psicología , Masculino , Persona de Mediana Edad , Tiroiditis/complicacionesRESUMEN
Many cases of acute flaccid paralysis occurred during an enterovirus D68 (EV-D68) outbreak in North America in the fall of 2014, and this epidemic has been newly defined as a distinct disease entity named acute flaccid myelitis (AFM). This disease entity is relatively popular among pediatricians, whereas it remains little-known among neurologists in Japan. We reported a 7-year-old girl with AFM, in whom severe limb weakness and respiratory failure developed five days after appearance of respiratory symptoms. Clinical features of our case were mimicked by those of acute axonal motor neuropathy at early stage of the disease, and this resulted in delayed diagnosis of AFM. DNA of EV-D68 was not detected. There are few reported cases of severe AFM, in which artificial ventilation is needed for a long time including both acute and recovery phases of the illness, and functional prognosis of AFM is discussed by literature.
Asunto(s)
Mielitis Transversa/terapia , Insuficiencia Respiratoria/terapia , Enfermedad Aguda , Niño , Diagnóstico Tardío , Enterovirus Humano D , Infecciones por Enterovirus/complicaciones , Extremidades , Femenino , Humanos , Debilidad Muscular/etiología , Mielitis Transversa/diagnóstico , Mielitis Transversa/etiología , Respiración Artificial , Insuficiencia Respiratoria/etiología , Índice de Severidad de la EnfermedadRESUMEN
A 60-years-old previously healthy man presented with acute renal failure and hemophagocytic lymphohistiocytosis (HLH). Both conditions improved after immunotherapies, but severe limb weakness with elevation of serum CK developed. Needle EMG showed myogenic changes with spontaneous activities and muscle weakness thereafter improved without adding further immunotherapies, suggesting that our patient had viral myositis. After the stabilization of limb weakness, cecal perforation occurred due to cytomegalovirus (CMV) enteritis and temporal significant change of anti-CMV IgG antibody titer was confirmed using paired serum samples. Upregulation of MHC-class I molecule and numerous regenerative muscle fibers were observed in muscle biopsy, but no evidence of direct CMV infection in muscle fibers were seen. Although CMV infection may cause either myositis, acute renal failure, HLH or colitis in individual patient, this is the first case which had been complicated by all these conditions subsequent to CMV infection.
Asunto(s)
Lesión Renal Aguda/etiología , Colitis/etiología , Infecciones por Citomegalovirus , Linfohistiocitosis Hemofagocítica/etiología , Miositis/complicaciones , Miositis/virología , Citomegalovirus/fisiología , Humanos , Perforación Intestinal/etiología , Persona de Mediana Edad , Activación ViralRESUMEN
Hashimoto's encephalopathy has been described as an autoimmune disorder which demonstrates favorable response to corticosteroid therapy. However, steroid-resistant cases which require additional treatment are frequently reported, and there is no consensus how such cases should be treated. We present a 69 years-old man, who progressed cognitive dysfunction in the past three months. Anti-thyroid and anti-NH2 terminal of alpha-enolase antibodies were positive. Because initial corticosteroid therapy was ineffective, cyclophosphamide (CPA) pulse therapy was added, and his cognitive function was immediately improved. He had no relapse after tapering dose of corticosteroid for three years. CPA pulse therapy should be considered for steroid-resistant Hashimoto's encephalopathy.